Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral V937 + Pembrolizumab in Advanced/Metastatic Solid Tumors
jRCT2033200191Phase 2Completed
- Sponsor
- MSD K.K.
- Start
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
01
Overview
Phase 2, open-label trial of pembrolizumab and coxsackievirus a21 in Nonhematologic neoplasms, triple-negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC) and 4 more (3 arms), sponsored by MSD K.K. Primary endpoints: Arm 1 Objective Response Rate (RECIST 1.1) and Arm 2 Safety, Tolerability, and RP2D Determination. Started Mar 2021; status: completed.
02
Drugs
pembrolizumabcoxsackievirus a21
03
Conditions
Nonhematologic neoplasmstriple-negative breast cancer (TNBC)head and neck squamous cell carcinoma (HNSCC)cutaneous squamous cell carcinoma (cSCC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2033200191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033200191.